Harris Teeter offers Rx savings
CHARLOTTE, N.C. Harris Teeter is offering customers more ways to save on their prescriptions.
The supermarket chain on Thursday announced an updated generic prescription savings club and the Harris Teeter Yourwellness savings card. The updated generic prescription savings club now offers customers a 30-day supply of generics for just $3.99, and has expanded its generic drug availabilities from 300 to 400 items. What’s more, Harris Teeter is providing up to a 30-day supply of five common generic diabetic medications for free. Enrollment is $4.95 per year.
Harris Teeter’s Yourwellness savings card, which costs $3.95 to enroll, offers shoppers savings on such health-and-wellness items as vitamins, eye care products and prescriptions. The new card program offers a choice of three plans: bronze, silver, or platinum.
Harris Teeter originally launched the yourwellness identity program in 2006. The goal, according to the company, is “to provide shoppers with evidence-based guidance on important health issues and to also help make it easier for shoppers to choose nutritional items in the store.”
Teva receives complete response letter for Neutroval
JERUSALEM The Food and Drug Administration declined to approve a Teva biosimilar, the generic drug maker said Thursday.
Teva said it received a complete response letter from the FDA concerning Neutroval (filgrastim), for neutropenia in patients receiving chemotherapy for cancer. The FDA issues complete response letters when it needs additional information before it can approve a drug.
Neutroval is a biosimilar of Amgen’s Neupogen and is marketed in Europe under the name TevaGrastim.
GSK halts Simplirix trial
LONDON British drug maker GlaxoSmithKline has stopped a late-stage trial of a vaccine for genital herpes, citing disappointing results, GSK said Thursday.
The company said that while the vaccine Simplirix (herpes simplex vaccine) proved to be safe when administered to women as a prevention for genital herpes disease, it did not prevent infection. GSK had been conducting the phase 3 trial in 8,323 women ages 18 to 30 years in the United States and Canada under a partnership with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
“We would like to express our gratitude toward our partner, [the National Institute of Allergy and Infectious Diseases], for [its] proactive collaboration and substantial contribution in the program, and the volunteers for their participation in the study,” GSK VP and director for late clinical development Gary Dubin said.